Skip to content

The Future is Now: Evolving Standards of Care in MIBC & la/mUC
TumorBoardTuesday MIBC Clinical Case Convo
Yüksel Ürün, MD & Emre Yekedüz, MD | 07/29/2025

***Post-survey, Evaluation, & Credit Claim***

In order to receive credit for this activity, you must read the front matter, view the activity, complete the post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.
1.Where are you in your career?(Required.)
2.What is your community of practice?
3.In the EV-103 Cohort H eval neoadj EV monotx in cis-inelig pts w/ #MIBC, 50% of pts achieved path downstaging. What was the pCR rate?(Required.)
4.➡️🧐65yo pt w/ MIBC
➡️ECOG PS 2
➡️CrCl 39 mL/minute

🗳️According to the criteria developed by Jiang et al, would this patient be considered cisplatin-eligible in the neoadj setting❓(Required.)
EVALUATION FORM
5.Approximately how many patients with bladder cancer do you currently see each week?
6.Upon completion of this activity, I am able to:
Strongly agree
Agree
Disagree
Strongly disagree
Analyze the role of antibody-drug conjugates and their potential to address unmet needs for additional therapy options in earlier stages of urothelial carcinoma.
7.Please indicate the extent of your agreement with the following statements:
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
The faculty were effective in presenting the material
Information in this activity is relevant to my clinical practice
The activity increased my knowledge on this topic
The activity provided appropriate and effective opportunities for active learning (e.g., case studies, discussion, Q&A, etc.)
The opportunities provided to assess my own learning were appropriate (e.g., questions before, during or after the activity)
8.Please rate your level of agreement by selecting the appropriate rating:
The content presented:
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Was scientifically rigorous and evidence based
Was fair, balanced, objective, and free of commercial bias
9.Based upon your participation in this activity, do you intend to change your practice behavior?
10.How confident are you that you will be able to make your intended changes?
11.Which of the following do you anticipate will be the primary barrier to implementing these changes? (check all that apply):
12.Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities:
13.For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*(Required.)
14.I certify that I have participated in the continuing education activity entitled, "MIBC Clinical Case Convo" and claim 1.0 AMA PRA Category 1 CreditTM.(Required.)
Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4-6 weeks to receive your certificate. 

For information about the certification of this program, please contact Partners for Advancing Clinical Education (PACE) at contactus@partnersed.com.
Privacy & Cookie Notice